Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
SinoMab Bioscience Ltd. ( (HK:3681) ) just unveiled an announcement.
SinoMab BioScience has agreed to terminate a 20-year lease for its Haikou manufacturing facility with connected party Haikou Pharmaceutical, effective 12 March 2026, requiring its subsidiaries to vacate the premises within 15 days. The move follows prolonged negotiations and is framed as part of the company’s shift toward a light-asset manufacturing model.
Under this strategy, drug candidates previously produced at the Haikou site for pre-clinical and clinical use will be outsourced to contract development and manufacturing organizations, which the board expects will deliver significant cost advantages. The company says derecognition of the right-of-use asset under accounting rules will be treated as a disposal, but it does not anticipate any material adverse impact on its financial position or operations, positioning the change as beneficial for shareholders while constituting a connected transaction under listing regulations.
The most recent analyst rating on (HK:3681) stock is a Sell with a HK$1.50 price target. To see the full list of analyst forecasts on SinoMab Bioscience Ltd. stock, see the HK:3681 Stock Forecast page.
More about SinoMab Bioscience Ltd.
SinoMab BioScience Limited is a Hong Kong–incorporated biopharmaceutical company listed on the Main Board of the Hong Kong Stock Exchange. The group focuses on the research, development, manufacturing and commercialization of therapeutics for immunological diseases, with a primary emphasis on monoclonal antibody-based biologics targeting global and Chinese markets.
Average Trading Volume: 5,138,425
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.61B
Find detailed analytics on 3681 stock on TipRanks’ Stock Analysis page.